Home Newsfeeds Piper Sandler Maintains Overweight on HubSpot, Raises Price Target to $450

Piper Sandler Maintains Overweight on HubSpot, Raises Price Target to $450

Piper Sandler analyst Brent Bracelin maintains HubSpot (NYSE:HUBS) with a Overweight and raises the price target from $350 to $450.

byBenzinga Newsdesk

February 17, 2023

1 minute read

Piper Sandler analyst Brent Bracelin maintains HubSpot (NYSE:HUBS) with a Overweight and raises the price target from $350 to $450.

Chemomab Shares Surge After Positive Data From NASH Biomarker Trial

By Vandana Singh

January 3, 11:27 AM

Chemomab Therapeutics Ltd (NASDAQ: CMMB) reported topline results from its Phase 2a trial assessing CM-101 in non-alcoholic steatohepatitis (NASH) patients.

CMMB

BWS Financial Maintains Buy on Ubiquiti, Raises Price Target to $375

By Benzinga Newsdesk

September 6, 9:48 AM

BWS Financial analyst Hamed Khorsand maintains Ubiquiti (NYSE:UI) with a Buy and raises the price target from $345 to $375.

Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial

By Vandana Singh

August 17, 2:28 PM

Sanofi SA (NASDAQ:SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5…

PFE

Top 4 Defensive Stocks That May Fall Off A Cliff In December

By Avi Kapoor

December 15, 9:41 AM

As of Dec. 15, 2023, four stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

COKE

Piper Sandler Maintains Overweight on HubSpot, Raises Price Target to $450

Related Posts

Chemomab Shares Surge After Positive Data From NASH Biomarker Trial

BWS Financial Maintains Buy on Ubiquiti, Raises Price Target to $375

Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial

Top 4 Defensive Stocks That May Fall Off A Cliff In December